share_log

Bristol-Myers Squibb | CORRESP: CORRESP

SEC announcement ·  Feb 17 05:33
Summary by Futu AI
Bristol-Myers Squibb Company (BMS) has responded to a comment letter from the U.S. Securities and Exchange Commission (SEC) regarding its tender offer statement for RayzeBio, Inc., initially filed on January 25, 2024. The SEC's letter, dated February 14, 2024, raised concerns about BMS's financing plans, the conditions of the offer, and the acceptance of tenders from shareholders in compliance with jurisdictional laws. BMS, along with its wholly owned subsidiary Rudolph Merger Sub Inc., has filed an amendment to the tender offer statement, addressing the SEC's comments and confirming their intention to comply with Commission rules and regulations. The amendment includes revised disclosures about the source and amount of funds, the conditions to the offer, and the acceptance of tenders from shareholders. BMS has assured the SEC that it will promptly inform RayzeBio stockholders of any developments that may affect the satisfaction of offer conditions.
Bristol-Myers Squibb Company (BMS) has responded to a comment letter from the U.S. Securities and Exchange Commission (SEC) regarding its tender offer statement for RayzeBio, Inc., initially filed on January 25, 2024. The SEC's letter, dated February 14, 2024, raised concerns about BMS's financing plans, the conditions of the offer, and the acceptance of tenders from shareholders in compliance with jurisdictional laws. BMS, along with its wholly owned subsidiary Rudolph Merger Sub Inc., has filed an amendment to the tender offer statement, addressing the SEC's comments and confirming their intention to comply with Commission rules and regulations. The amendment includes revised disclosures about the source and amount of funds, the conditions to the offer, and the acceptance of tenders from shareholders. BMS has assured the SEC that it will promptly inform RayzeBio stockholders of any developments that may affect the satisfaction of offer conditions.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1

The information provided by Futu AI is automatically generated by third-party artificial intelligence (AI) software based on news content. It is only available to users located outside of China mainland.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.